2Sil*a I, Branco JC. RANK/RANKL/OPG: literature review [J]. Acta Reumatol Port,2011, 36(3) :209-218.
3Keams AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease [J]. Endocr Rev, 2008,29(2) :155-192.
4Kbosla S. Minireview: the OPG/RANKL/RANK system [ J ]. Endocrinology,2001,142 (12) :5050-5055.
5Wada T, Nakashima T, Hiroshi N, et al. RANKL-RANK signaling in osteoclastogenesis and bone disease [ J ]. Trends Mol Med, 2006, 12(1) :17-25.
6Collin-Osdoby P, Rothe L, Anderson F, et al. Receptor ac- tivator of NF-kappa B and osteoprotegerin expression by hu- man microvascular endothelial cells, regulation by inflamma- tory eytokines, and role in human osteoclastogenesis [ J ]. J Biol Chem,2001,276(23) :20659-20672.
7Simonct WS, Lacey DL, Dunstan CR, et al. Osteoprote- gerin: a novel secreted protein involved in the regulation of bone density[J]. Cell, 1997,89(2) :309-319.
8Ostrowski MC. A new role for OPG: putting RANKL in its place[J]. J Bone Miner Res,2010,25(9) :1905-1906.
